[go: up one dir, main page]

WO2007002359A3 - Methods for identifying delta subunit-containing gaba receptor modulatory agents - Google Patents

Methods for identifying delta subunit-containing gaba receptor modulatory agents Download PDF

Info

Publication number
WO2007002359A3
WO2007002359A3 PCT/US2006/024420 US2006024420W WO2007002359A3 WO 2007002359 A3 WO2007002359 A3 WO 2007002359A3 US 2006024420 W US2006024420 W US 2006024420W WO 2007002359 A3 WO2007002359 A3 WO 2007002359A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
gaba receptor
containing gaba
modulatory agents
delta subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/024420
Other languages
French (fr)
Other versions
WO2007002359A2 (en
Inventor
Martin Wallner
Richard W Olsen
Harry J Hanchar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2007002359A2 publication Critical patent/WO2007002359A2/en
Publication of WO2007002359A3 publication Critical patent/WO2007002359A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides methods of identifying agents that modulate δ subunit-containing GABA receptor activity. The agents so identified find use in a variety of research and treatment methods.
PCT/US2006/024420 2005-06-24 2006-06-21 Methods for identifying delta subunit-containing gaba receptor modulatory agents Ceased WO2007002359A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69384405P 2005-06-24 2005-06-24
US60/693,844 2005-06-24
US78283406P 2006-03-15 2006-03-15
US60/782,834 2006-03-15

Publications (2)

Publication Number Publication Date
WO2007002359A2 WO2007002359A2 (en) 2007-01-04
WO2007002359A3 true WO2007002359A3 (en) 2007-06-07

Family

ID=37595848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/024420 Ceased WO2007002359A2 (en) 2005-06-24 2006-06-21 Methods for identifying delta subunit-containing gaba receptor modulatory agents

Country Status (1)

Country Link
WO (1) WO2007002359A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059648A1 (en) * 2011-10-21 2013-04-25 Neurotherapeutics Pharma, Inc. 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052365A1 (en) * 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents
US6555341B1 (en) * 1997-04-25 2003-04-29 Merck Sharp & Dohme Ltd. Human theta subunit of the GABAa receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555341B1 (en) * 1997-04-25 2003-04-29 Merck Sharp & Dohme Ltd. Human theta subunit of the GABAa receptor
US20020052365A1 (en) * 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEHTA ET AL.: "Ethanol potentiation of GABAergic transmission in cultured spinal cord neurons involves gamma-aminobutyric acidA-gated chloride channels", AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 246, no. 2, August 1988 (1988-08-01), pages 5558 - 564, XP008081834 *

Also Published As

Publication number Publication date
WO2007002359A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
EP2881082B8 (en) Systems and devices for treating pelvic floor disorders
TWI368177B (en) Methods and systems for integration of multiple rewards programs
EP1835929B8 (en) Anti-kir combination treatments and methods
AU2003282679A1 (en) Hydroxypyrazoles for use against metabolic-related disorders
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2008097525A3 (en) Local complement inhibition for treatment of complement-mediated disorders
WO2010060937A3 (en) Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
EP1651251A4 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
WO2007145704A3 (en) Gemcitabine combination therapy
WO2007089715A3 (en) Method for treatment of neuropathic pain
SI1761266T1 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
WO2009009587A3 (en) Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same
WO2008011487A3 (en) L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
WO2005072713A3 (en) Cholinesterase inhibitors for treating inflammation
WO2006055871A3 (en) Treatment for multiple sclerosis
WO2004087066A3 (en) Hif-1 inhibitors
EP1922086A4 (en) Targeted protein kinase c inhibitors and uses thereof
EP2564864B8 (en) FGF2-related methods for diagnosing and treating depression
WO2007023310A3 (en) Stimulation of neurogenesis with help of alk inhibitors
WO2007002359A3 (en) Methods for identifying delta subunit-containing gaba receptor modulatory agents
EP1755637B8 (en) Methods for preventing or treating bone disorders
WO2007015173A3 (en) Inflammation
WO2006074443A3 (en) Pde5 inhibitor compositions and methods for immunotherapy
WO2007010013A3 (en) Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06799957

Country of ref document: EP

Kind code of ref document: A2